1 completed, 1 terminated. 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Completed 1, Terminated 1 |
Follow Recurrent T-Cell Prolymphocytic Leukemia: new trials by email Literature Review of Recurrent T-Cell Prolymphocytic Leukemia trials Research Report on Recurrent T-Cell Prolymphocytic Leukemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Fludarabine, Cytarabine, and Pegcrisantaspase for the Treament of Relapsed or Refractory Leukemia Cytarabine, Fludarabine, Pegcrisantaspase - Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Recurrent Acute Biphenotypic Leukemia | Phase 1 | Terminated | M.D. Anderson Cancer Center | 19 | 2021-04-09 | 2024-12-12 |
| Itacitinib and Alemtuzumab in Treating Patients With T-Cell Prolymphocytic Leukemia Alemtuzumab, Itacitinib - Recurrent T-Cell Prolymphocytic Leukemia, T-Cell Prolymphocytic Leukemia | Phase 1 | Completed | M.D. Anderson Cancer Center | 15 | 2020-01-15 | 2024-10-10 |
Leukemia, Prolymphocytic, T-Cell (2) · Blast Crisis (1) · Leukemia, Biphenotypic, Acute (1) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (1) · Leukemia, Myeloid, Acute (1) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (1)
Hematologic Diseases (2) · Hemic and Lymphatic Diseases (2) · Immune System Diseases (2) · Immunoproliferative Disorders (2) · Leukemia (2) · Leukemia, Lymphoid (2) · Leukemia, Prolymphocytic (2) · Leukemia, T-Cell (2) · Lymphatic Diseases (2) · Lymphoproliferative Disorders (2) · Neoplasms (2) · Neoplasms by Histologic Type (2) · Bone Marrow Diseases (1) · Carcinogenesis (1) · Cell Transformation, Neoplastic (1)
Alemtuzumab (1) · Cytarabine (1) · INCB039110 (1) · fludarabine (1) · itacitinib (1)
M.D. Anderson Cancer Center (2)
United States (2)
Tapan M Kadia (2)